Janssen Pharmaceutica Nv

Alan Richardson

Eddy Jean Edgard Freyne

Chih Yung Ho

Jean Fernand Armand Lacrampe

Peter Jacobus Johannes Buijnsters

Richard William Connors

Stefan Leo Jozef Masure

Annette Cornelia Bakker

The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m, n, R, R, R, Rand Rare as defined herein, the use of such compounds as inhibitors of cyclin-dependent serine/threonine kinases (Cdks), as well as kinases and phosphatases involved in cell cycle regulation such as the tyrosine kinases Wee1, Mik1 and Myt1 or the tyrosine dephosphatases such as Cdc25 and Pyp3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating cell proliferative disorders such as atherosclerosis, restenosis and cancer.

3-furanyl analogs of toxoflavine as kinase inhibitors

There is disclosed a nucleic acid molecule encoding human Akt-3 protein or a functional equivalent or bioprecursor thereof comprising the amino acid sequence illustrated in Sequence ID No. 3. The human Akt-3 protein itself also forms part of the invention. The nucleic acid molecule and the human Akt-3 protein may themselves be used as medicaments, or in the preparation of medicaments for treating cancer, in their own right or in the form of a pharmaceutically acceptable carrier, diluent or excipient thereof. Further disclosed are methods of identifying agents which influence the activity of a human Akt-3 protein.

Human Akt-3

Growing community of inventors

Buckingham, United Kingdom

Alan Richardson